US FDA approves Adapt's Narcan nasal spray for opioid overdose

The US Food and Drug Administration has approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose, developed by Ireland-based Adapt Pharma.

Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin. For more than 40 years, naloxone has been trusted by healthcare providers for reversing the effects of opioid overdose, but until today, it was FDA approved only as an injection.

NRCAN nasal spray, a ready-to-use, needle-free device, delivers a 4mg dose of naloxone in a single 0.1ml nasal spray. Narcan nasal spray requires no assembly or priming prior to use. Adapt Pharma says it is committed to affordable and transparent pricing of Narcan Nasal Spray. Group purchasers, such as law enforcement, fire fighters, first responders, departments of health, local school districts, colleges and universities, and community-based organizations that order directly from Adapt Pharma, are eligible for a discounted Public Interest |Price of $37.50 per 4mg Narcan device ($75 for a carton containing two devices of Narcan nasal spray 4mg).